MSD Announces Positive Study Investigating the Use of Pembrolizumab Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma
Dateline City:
ZURICH
Pembrolizumab Demonstrated Superiority to Chemotherapy for Primary Endpoint of Progression-Free Survival
Findings Presented for First Time at Society of Melanoma Research (SMR) 2014 International Congress
ZURICH--(BUSINESS WIRE)--MSD, known as Merck in the United States and Canada, announced today
that a pre-specified analysis of investigational data from a pivotal
Phase 2 study (KEYNOTE-002) showed pembrolizumab, the company’s
anti-PD-1 therapy, substantially improved the primary endpoint of
progression-free survival (PFS, as assessed by RECIST 1.1, independent
central review) (HR 0.57 and 0.50 for 2 mg/kg and 10 mg/kg every three
week doses, respectively), compared to chemotherapy (P<0.0001 for both
comparisons) in patients with ipilimumab-
Language:
English
Contact:
MSDMedia:Lainie Keller, +1-908-236-5036Claire Mulhearn, +1-908-236-1118orInvestor:Joseph Romanelli, +1-908-423-5185Justin Holko, +1-908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News Source Type: news
More News: Cancer & Oncology | Chemotherapy | Melanoma | Merck | Pharmaceuticals | Politics | Skin Cancer | Study | Yervoy